Literature DB >> 9358749

Time course and localization of endothelin-1 gene expression in a model of renal disease progression.

I Bruzzi1, D Corna, C Zoja, S Orisio, E L Schiffrin, D Cavallotti, G Remuzzi, A Benigni.   

Abstract

Experimental and human proteinuric glomerulopathies are associated with tubulo-interstitial injury that correlates with the decline of renal function even better than glomerular lesions do. Mechanism(s) leading to tubulo-interstitial damage are unknown. It has been proposed that excessive reabsorption of filtered proteins activates renal cells to produce vasoactive and inflammatory molecules including endothelin-1. The aim of the present study was twofold: we first evaluated the cellular origin of excessive renal endothelin-1 production in the renal mass reduction model and then related endothelin-1 distribution to the development of kidney lesions. Four groups of renal mass reduction (n = 15) and four groups of control rats (n = 5) were studied at 7, 14, 21, and 28 days after surgery. Urinary proteins in renal mass reduction rats were comparable with controls at day 7 but became significantly higher thereafter. Renal mass reduction rats first developed tubulo-interstitial changes, which were already evident at day 14 in the majority of them. At 28 days, renal mass reduction rats also developed glomerulosclerosis. A parallel increase of renal endothelin-1 gene expression and synthesis of the corresponding peptide in renal mass reduction rats versus controls was observed from day 14. Nonradioactive in situ hybridization confirmed a pattern of endothelin-1 mRNA consistent with the distribution of lesions. At day 14, endothelin-1 staining was stronger in renal mass reduction than in control kidneys and mainly localized to the cytoplasm of tubular cells, whereas glomeruli were negative. At day 28, endothelin-1 expression further increased in renal mass reduction rats as compared with controls, and the staining was apparent also in glomeruli. Thus, in renal mass reduction, a progressive up-regulation of endothelin-1 occurs during the development of renal injury, that first involves the tubules and, only in a subsequent phase, the glomeruli.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358749      PMCID: PMC1858100     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Renal and systemic nitric oxide synthesis in rats with renal mass reduction.

Authors:  S Aiello; M Noris; M Todeschini; S Zappella; C Foglieni; A Benigni; D Corna; C Zoja; D Cavallotti; G Remuzzi
Journal:  Kidney Int       Date:  1997-07       Impact factor: 10.612

2.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.

Authors:  S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

3.  Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.

Authors:  C Zoja; D Corna; I Bruzzi; C Foglieni; T Bertani; G Remuzzi; A Benigni
Journal:  Exp Nephrol       Date:  1996 Jul-Aug

4.  Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy.

Authors:  J J Morrissey; S Ishidoya; R McCracken; S Klahr
Journal:  J Am Soc Nephrol       Date:  1996-10       Impact factor: 10.121

5.  Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins.

Authors:  C Zoja; M Morigi; M Figliuzzi; I Bruzzi; S Oldroyd; A Benigni; P Ronco; G Remuzzi
Journal:  Am J Kidney Dis       Date:  1995-12       Impact factor: 8.860

6.  Tubulo-interstitial alterations in type I membranoproliferative glomerulonephritis. An investigation of 259 cases.

Authors:  H Schmitt; V Cavalcanti de Oliveira; A Bohle
Journal:  Pathol Res Pract       Date:  1987-02       Impact factor: 3.250

7.  Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney.

Authors:  A Benigni; C Zola; D Corna; S Orisio; D Facchinetti; L Benati; G Remuzzi
Journal:  Am J Kidney Dis       Date:  1996-03       Impact factor: 8.860

8.  Contribution on the correlation between morphometric parameters gained from the renal cortex and renal function in IgA nephritis.

Authors:  S Mackensen-Haen; R Eissele; A Bohle
Journal:  Lab Invest       Date:  1988-08       Impact factor: 5.662

9.  Proteinuria induced by transplantable rat pituitary tumor MtT SA5. Model for homologous protein-overload proteinuria.

Authors:  H Mori; H Yamashita; C Nakanishi; K Koizumi; S Makino; Y Kishimoto; Y Hayashi
Journal:  Lab Invest       Date:  1986-06       Impact factor: 5.662

10.  An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration.

Authors:  A C Ong; T P Jowett; J D Firth; S Burton; F E Karet; L G Fine
Journal:  Kidney Int       Date:  1995-08       Impact factor: 10.612

View more
  6 in total

Review 1.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

3.  Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis.

Authors:  H C Chen; J Y Guh; J M Chang; J C Tsai; S J Hwang; Y H Lai
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

4.  Deficiency in Six2 during prenatal development is associated with reduced nephron number, chronic renal failure, and hypertension in Br/+ adult mice.

Authors:  Ben Fogelgren; Shiming Yang; Ian C Sharp; Odaro J Huckstep; Wenbin Ma; S J Somponpun; Edward C Carlson; Catherine F T Uyehara; Scott Lozanoff
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-04

5.  Glycosuria and Renal Outcomes in Patients with Nondiabetic Advanced Chronic Kidney Disease.

Authors:  Chi-Chih Hung; Hugo You-Hsien Lin; Jia-Jung Lee; Lee Moay Lim; Yi-Wen Chiu; Heng-Pin Chiang; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

Review 6.  Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.

Authors:  Ariela Benigni; Simona Buelli; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2020-03-17       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.